Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 247,100 shares, an increase of 1,730.4% from the January 31st total of 13,500 shares. Based on an average daily trading volume, of 378,900 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Several analysts recently commented on the company. Maxim Group reaffirmed a “hold” rating on shares of Aclarion in a research note on Friday, December 13th. Ascendiant Capital Markets reduced their target price on shares of Aclarion from $502.50 to $435.50 and set a “buy” rating on the stock in a research note on Wednesday, November 27th.

Aclarion Price Performance

Aclarion stock traded down $0.08 during trading hours on Thursday, hitting $3.22. 101,582 shares of the stock were exchanged, compared to its average volume of 648,956. The business’s 50-day moving average is $17.17 and its two-hundred day moving average is $46.32. Aclarion has a 12 month low of $3.03 and a 12 month high of $231.15.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.